Hi, good evening, and congratulations for an extremely strong set of numbers. A couple of questions. One, we read a lot around shortages in the U.S., both around injectables as well as the oral solids. There seems to be a fair bit of traction from regulators and state actors as well. But, I mean, you being there, are you witnessing anything structurally changing in this market? Second, versus how things were, say, a year back, how have things evolved and how do you see these things moving forward? So those are two sub - questions. And second, if you could give us some sense on what's happening with your biosimilars business? Thank you.
Questions across 2 calls
Tarang Agrawal
Firm not listed in source transcripts
Lupin Limited
Aurobindo Pharma Limited
Hi, good morning. Am I audible?
So there’s a deferred tax asset that’s getting created, is it, for all these?